Moderate-dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution

First-line therapy of severe aplastic anemia (SAA) with high-dose cyclophosphamide causes toxicity and increased short-term mortality. We investigated cyclophosphamide at a lower, more moderate dose in combination with aggressive supportive care to determine whether severe infections might be avoide...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Scheinberg, Phillip, Townsley, Danielle, Dumitriu, Bogdan, Scheinberg, Priscila, Weinstein, Barbara, Daphtary, Maithili, Rios, Olga, Wu, Colin O., Young, Neal S.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2014
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4215312/
https://ncbi.nlm.nih.gov/pubmed/25185712
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-05-573642
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky